Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

• Status: Completed
• Trial end date: 2004-12-08
• Target enrollment: 0
• Participant gender: Male

Summary

To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rofecoxib

Criteria

Regular PSA testing and study biopsies required.